Grover DS, et al. – The goal of the study described in this paper was to assess the intraocular pressure (IOP)–lowering performance and safety of an ab interno gelatin stent (XEN® 45 Gel Stent, Allergan plc), a minimally invasive glaucoma surgery device, in refractory glaucoma. The current study showed that the gelatin stent decreased IOP and medication use without raising unexpected safety concerns, offering a minimally invasive surgical option for refractory glaucoma patients.